1. Home
  2. SKYE vs LOOP Comparison

SKYE vs LOOP Comparison

Compare SKYE & LOOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • LOOP
  • Stock Information
  • Founded
  • SKYE 2012
  • LOOP 2010
  • Country
  • SKYE United States
  • LOOP Canada
  • Employees
  • SKYE N/A
  • LOOP N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • LOOP Major Chemicals
  • Sector
  • SKYE Health Care
  • LOOP Industrials
  • Exchange
  • SKYE Nasdaq
  • LOOP Nasdaq
  • Market Cap
  • SKYE 73.4M
  • LOOP 82.6M
  • IPO Year
  • SKYE N/A
  • LOOP N/A
  • Fundamental
  • Price
  • SKYE $2.16
  • LOOP $1.65
  • Analyst Decision
  • SKYE Buy
  • LOOP
  • Analyst Count
  • SKYE 6
  • LOOP 0
  • Target Price
  • SKYE $16.60
  • LOOP N/A
  • AVG Volume (30 Days)
  • SKYE 229.4K
  • LOOP 367.9K
  • Earning Date
  • SKYE 08-08-2025
  • LOOP 07-14-2025
  • Dividend Yield
  • SKYE N/A
  • LOOP N/A
  • EPS Growth
  • SKYE N/A
  • LOOP N/A
  • EPS
  • SKYE N/A
  • LOOP N/A
  • Revenue
  • SKYE N/A
  • LOOP $10,889,000.00
  • Revenue This Year
  • SKYE N/A
  • LOOP N/A
  • Revenue Next Year
  • SKYE N/A
  • LOOP $592.45
  • P/E Ratio
  • SKYE N/A
  • LOOP N/A
  • Revenue Growth
  • SKYE N/A
  • LOOP 7016.99
  • 52 Week Low
  • SKYE $1.14
  • LOOP $0.85
  • 52 Week High
  • SKYE $9.73
  • LOOP $2.34
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 51.61
  • LOOP 64.11
  • Support Level
  • SKYE $2.12
  • LOOP $1.55
  • Resistance Level
  • SKYE $2.22
  • LOOP $1.67
  • Average True Range (ATR)
  • SKYE 0.19
  • LOOP 0.20
  • MACD
  • SKYE -0.02
  • LOOP 0.00
  • Stochastic Oscillator
  • SKYE 34.69
  • LOOP 38.94

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About LOOP Loop Industries Inc.

Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.

Share on Social Networks: